相似文献
1
How basic scientists help the pharmaceutical industry market drugs.
PLoS Biol. 2013 Nov;11(11):e1001716. doi: 10.1371/journal.pbio.1001716. Epub 2013 Nov 19.
2
A venture capital view of challenges, opportunities, and innovation in biomedical research.
Clin Pharmacol Ther. 2011 Feb;89(2):174-6. doi: 10.1038/clpt.2010.284.
3
Industry funded clinical trials: bias and quality.
Curr Med Res Opin. 2012 Jan;28(1):23-5. doi: 10.1185/03007995.2011.628651. Epub 2011 Nov 21.
4
Knowledge industry: a powerful mechanism.
Rev Saude Publica. 2010 Feb;44(1):190-6. doi: 10.1590/s0034-89102010000100021.
5
[Financial conflict of interest in clinical psychiatry studies: a review].
Turk Psikiyatri Derg. 2008 Winter;19(4):418-26.
6
Public sector seeks to bridge 'valley of death'.
Nat Biotechnol. 2007 Mar;25(3):266. doi: 10.1038/nbt0307-266. Epub 2007 Mar 1.
7
Medical ethics, research and the pharmaceutical industry.
Reumatol Clin. 2012 Sep-Oct;8(5):233-5. doi: 10.1016/j.reuma.2011.12.010. Epub 2012 May 17.
8
Conflict of interest and its significance in science and medicine.
Natl Cathol Bioeth Q. 2002 Summer;2(2):315-7.
9
Sponsorship bias in clinical research.
Int J Risk Saf Med. 2012;24(4):233-42. doi: 10.3233/JRS-2012-0574.
10
Considering industry-sponsored research.
Am J Phys Med Rehabil. 2009 Apr;88(4):342-8. doi: 10.1097/PHM.0b013e31819111ec.
引用本文的文献
1
Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research.
BMC Med Ethics. 2015 Jul 28;16:53. doi: 10.1186/s12910-015-0043-7.
本文引用的文献
1
Promoting "low T": a medical writer's perspective.
JAMA Intern Med. 2013 Aug 12;173(15):1458-60. doi: 10.1001/jamainternmed.2013.6892.
2
Evaluation of excess significance bias in animal studies of neurological diseases.
PLoS Biol. 2013 Jul;11(7):e1001609. doi: 10.1371/journal.pbio.1001609. Epub 2013 Jul 16.
3
Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents.
Swiss Med Wkly. 2013 May 7;143:w13776. doi: 10.4414/smw.2013.13776. eCollection 2013.
4
Biomedical research in an age of austerity.
JAMA. 2012 Dec 12;308(22):2341-2. doi: 10.1001/jama.2012.14846.
5
Industry sponsorship and research outcome.
Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033. doi: 10.1002/14651858.MR000033.pub2.
6
Erythropoietin or darbepoetin for patients with cancer.
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5.
7
Frequency and factors influencing publication of abstracts presented at three major nephrology meetings.
Int Arch Med. 2011 Dec 6;4(1):40. doi: 10.1186/1755-7682-4-40.
8
Publication patterns of oral and poster presentations at the annual meetings of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons.
J Neurosurg. 2011 Dec;115(6):1258-61. doi: 10.3171/2011.7.JNS101538. Epub 2011 Aug 26.
9
Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles.
PLoS Med. 2010 Aug;8(8):e1001070. doi: 10.1371/journal.pmed.1001070. Epub 2011 Aug 2.
10
The haunting of medical journals: how ghostwriting sold "HRT".
PLoS Med. 2010 Sep 7;7(9):e1000335. doi: 10.1371/journal.pmed.1000335.
Zotero 插件